Neumora Therapeutics, Inc.

Ladies and gentlemen, thank you for standing by. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to turn the conference over to Helen Rubenstein, Vice President of Investor Relations and Communications. Please go ahead.

Good afternoon, and thank you for joining New Moora Therapeutics' First Quarter 2025 Financial Results Conference Call. Before we begin, I encourage everyone to go to the Investors and Media section of our website at numoratx.com, where you can find the press release related to today's call. With me from New Moora are Chief Executive Officer Paul Burns, President Josh Pinto, Chief Operating and Development Officer Bill Aurora, and Chief Financial Officer Mike Milligan. I'd like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. Please review the risk factors discussed in today's press release and in our SEC filings for additional detail. With that, I'll now turn the call over to Paul.

Thanks, Helen. Good afternoon, everyone, and thank you for joining us. At New Moora, we believe the greatest medical challenge of our generation is the global brain disease crisis. This affects upwards of 1.5 billion people and causes a severe impact on quality of life, not only for patients, but also their families and society at large. Despite a number of approved therapies, there is a significant outstanding unmet need for safe and effective treatment options to alleviate the burdens of these diseases. When we founded New Moora, it was with the intention to confront this challenge head-on and focus on bringing novel mechanisms forward to redefine neuroscience drug development. We have made important progress towards that goal. We are advancing an industry-leading pipeline of programs all targeting novel mechanisms of action with the potential to address some of the most prevalent brain diseases and are supported by a strong financial foundation. As we are poised to achieve a number of upcoming clinical catalysts across our pipeline, I believe we have the right science, people, and strategy in place to realize our vision of revolutionizing the treatment of brain diseases. I will now turn the call over to Josh Pinto, President of New Moora, to review our business and pipeline updates. Josh?

Thanks, Paul. We are focused on clinical execution as we are advancing multiple programs towards key milestones over the next 12 months. We are on track to deliver top-line data for NMRA 511, our vasopressin 1A receptor antagonist in Alzheimer's disease agitation around the end of the year. We are also progressing the VACA Pran in the Phase III coastal program in MDD, where we have implemented important changes for the ongoing studies and plan to report top-line data from Coastal 3 in the first quarter of 2026 and Coastal 2 in the second quarter of 2026. In our M4 franchise, we are working with urgency to bring a -in-class M4 PAM into the clinic in the middle of this year. Additionally, we announced this morning that we entered into a $125 million debt facility with K2 Health Ventures, with up to $40 million available for draw this year. K2 Health Ventures has deep expertise in life sciences, and we are pleased with the opportunity to work with their team. Financial discipline has always been a core tenet of how we operate our business, and today it is more important than ever to maintain diligent stewardship of capital. The non-dilutive capital from this facility, combined with the cash already on our balance sheet, further strengthens our financial position and will support our efforts to achieve value-creating milestones across our pipeline. With this update, we now expect our cash, cash equivalents, and marketable securities, together with the $20 million funded at close under the K2 facility, to support our operations into 2027, well beyond anticipated clinical data milestones. As you can see, we are well positioned to generate value from a number of programs, and we are supported by a strong financial foundation. Each one of our programs evaluates a novel mechanism of action in their respective indications, with the potential to bring new treatment options to patients and capitalize on significant market opportunities. Our pipeline is supported by very strong intellectual property portfolios with worldwide rights to all of our programs and composition of matter patents extending into the 2040s. As a multi-product company with multiple shots on goal, we are prepared to execute against their vision of maximizing all pathways for success and generating long-term company growth. With that overview, I will now turn the call over to Bill to provide additional details on our clinical programs. Bill?

Thanks, Josh. We are excited about the industry-leading pipeline we have constructed and the potential of these novel mechanisms to revolutionize the treatment of brain diseases. Starting with Nalvacoprant, we are confident in the potential for Nalvacoprant to become a differentiated treatment option for patients with MDD. There is a strong body of clinical evidence validating the potential of kappa-opioid receptor antagonists to show benefit in MDD and anhedonia. Supporting studies include the National Institute of Health or NIH-run FastMAS study, the J&J Phase II study of Aticoprant, and importantly, our own Phase II study of Nalvacoprant, which was recently published in the Journal of Clinical Psychopharmacology. This publication highlights that Nalvacoprant demonstrated statistically significant and clinically meaningful reductions in symptoms of depression and anhedonia in participants with moderate to severe MDD. So, when trying to understand how COSTAL-1 results compared to other studies, we identified a few factors that were different from what you'd expect to see in a typical MDD population. For example, approximately two-thirds of the patients had never taken a prior antidepressant, despite experiencing an average of five prior episodes of MDD in their lifetimes. Prior trials and publications suggest that a substantially higher percentage of people with chronic MDD would have received prior antidepressant treatment. As we've looked at the data, we concluded that the total population in COSTAL-1 was not necessarily representative of the MDD population, and that's why we've made modifications in site selection, patient screening, and medical monitoring in COSTAL-2 and 3 to help ensure that appropriate patients are enrolled. The studies resumed enrolling in March with the following changes. We enhanced engagement with sites around medical monitoring to confirm the patients enrolled in the studies have an independently verified diagnosis of MDD that helps to ensure they appropriately meet eligibility criteria for these studies. We added the clinician rated Massachusetts General Hospital Clinical Trials Network and Institute SAFER approach, which is an independent review conducted by clinicians to verify the diagnosis and appropriateness of the patient population. Our internal medical team is partnering with the SAFER clinical team to confirm eligibility prior to randomization. We also added an additional tool called the Verified Clinical Trial Screening Database aimed at better identifying patients who are participating in multiple clinical trials and excluding them from enrolling in the COSTAL-2 and 3 studies. This is an additive step to the clinical trial subject database we used in COSTAL-1, and we believe it will help to ensure the appropriate patients are enrolled in our ongoing studies. And finally, we've reduced the number of clinical sites and selected those sites that we believe have the greatest level of expertise in conducting MDD studies. We have already seen benefits from these added measures in the COSTAL-2 and COSTAL-3 studies. For example, the Verified Clinical Trial Screening Database has identified multiple potential participants who are not appropriate for inclusion, enabling us to exclude them from the studies. More broadly, it's important to remember that many approved medicines in MDD and psychiatry broadly have failed individual phase three studies, but ultimately succeeded in multiple studies and become important treatments. We designed the COSTAL program with the historical challenges in mind, knowing that we would need two of the three trials to be successful in order to file an NDA. We anticipate data from COSTAL-3 in the first quarter of 2026 and COSTAL-2 in the second quarter of 2026. I also want to highlight our franchise of M4 PAMs that we are advancing, where we plan to move a candidate into the clinic in the middle of this year. Based on available data, it is clear that M4 is the driver of antipsychotic activity seen with muscarinic drugs today. We believe we are well positioned to become a leader in M4 PAMs that can potentially offer improved safety and tolerability profile and once a day dosing. We look forward to sharing more on the pharmacology of our M4 programs. When they enter the clinic in mid 2025. In phase 1B is our vasopressin 1A receptor antagonist, NMRA 511, which is a highly potent and highly selective antagonist being evaluated for Alzheimer's disease agitation. The V1A target is a proven pathway as it is known to play a role in the regulation of aggression, affiliation, stress and anxiety response. In preclinical data, NMRA 511 reduced measures of anxiety, agitation, aggression and was very well tolerated in a phase one sad man study as well as in healthy elderly volunteers. We believe that based on these data combined with findings from other sponsors, there's a strong rationale for NMRA 511 in AD agitation, an area of significant unmet need with only one approved agent that carries a black box warning. We look forward to delivering top line data from phase 1B signal seeking study around the end of this year. In parallel, we continue to progress our four preclinical programs, which have opportunity to make impacts in serious and common diseases, such as Parkinson's disease, Alzheimer's disease and ALS. Those programs are advancing and we look forward to sharing more information on those studies in the near future. In short, it has been a productive start to 2025 for NMRA and we're well positioned to achieve our multiple upcoming clinical catalysts in the second half of this year and beyond. With that, I'll now turn it over to Mike for a view of the financials. Mike.

Thanks Bill and good afternoon everyone. Our financial results for the first quarter of 2025 are detailed in the press release that we issued this morning. I'd like to take a moment to provide some context and highlight a few key points. Net loss for the first quarter was $68 million compared to $53.7 million for the same period in 2024. And we ended the quarter with $249.4 million in cash, cash equivalents and marketable securities as of March 31st, 2025. As Josh noted, we are focused on disciplined capital allocation and expect our cash on hand and the $20 million drawn at the close of the K-2 facility to support operations into 2027. We expect that this runway will allow us to realize multiple catalysts across our programs. With that, I'll now hand the call over to Helen to manage Q&A with the operator. Helen.

Thanks Mike. Before I turn it over to the operator, I'll ask that you limit yourself to one question. If you have an additional question, please feel free to return to the queue. Now I'll turn it over to the operator to handle Q&A. Operator.

As a reminder, if you'd like to ask a question at this time, please press star 1-1 on your telephone and wait for your name to be announced. To withdraw your question, please press star 1-1 again. Please stand by while we compile the Q&A roster. Our first question comes from Douglas Sout with HC Wainwright.

Hi, good afternoon. Thanks for taking the questions. I guess two for me. First, starting with the back of France, I understand the operational changes that were put in place. I'm just curious, have you had any sort of sense of how it has affected sort of the pace of enrollment, early going, just sort of early experiences that and sort of what gives you that confidence in terms of achieving the readouts next year?

Thanks Doug. Hi, this is Bill. Appreciate your question. We've already seen benefits from steps that we've taken with both SAFER and the Verified Clinical Trial Screening Database that we've implemented in the K-2 and the K-3 studies. Both have identified multiple potential participants who really aren't appropriate for inclusion in the study, enabling us to exclude these patients from being put in. So we do have confidence that the steps we're taking are helping to get

appropriate patients randomized to into K-2 and K-3.

And I guess Bill, as a follow up, is it having a negative impact in terms of the pace of enrollment or obviously you're sort of disqualifying some patients? And I guess it sounds like though that the rate of that is occurring at a rate consistent with what you were expecting.

Yes, it is consistent. The rate of those patients being excluded is consistent with our expectation. It doesn't impact our timing guidance that we've provided with respect to the enrollment. So things are progressing as planned.

Okay, great. That's great to hear. And then just on the K-2 financing, I'm just curious if you can provide any details in terms of sort of limitations on prepayment or just to the extent that as you hit other milestones, are you able to perhaps pay down that debt as sort of your cost of equity comes down?

Thank

you.

Hey, Doug, it's Josh here. I'll take that one. And the details of the facility are disclosed in our 10-cube. So I would point you towards that. But really with this facility, what we were looking to achieve in this financing was extending our cash runway into 2027. And so with the 20 million that we're able to draw close plus our existing cash balance, we were able to achieve that goal and we've extended our cash runway now into 2027. In terms of the milestones, you can think about progression of Novaka Prant through some of the clinical stages as well as some regulatory stages as ways to ungate additional capital. But as we noted in the press release, beyond the first 20 million that was funded at close, there will be another 20 million that we can bring in at our discretion before the end of this year. So there is flexibility in terms of bringing more capital onto our balance sheet this year through the facility.

And Josh, just to confirm though, you only need the 20 million to get you into 2027.

Correct, our existing cash balance sheet as of the end of March plus the 20 million funded at close gets our runway into 2027. So any additional drawdowns beyond that would provide funding for additional investments or extension of the cash runway beyond that.

Okay, great, thank you so much.

Our next question comes from Yaten Sunehya with Guggenheim.

Hey guys, thank you for taking my question. A couple of questions on coastal program. Could you talk about the patient population who might have received an antidepressant in this, how you are tracking it? Because as I recall in coastal one, there was a lot of patients that had never taken antidepressant therapy in the past. So just curious to know, is there a particular percentage of patients that you're targeting who would have taken a prior antidepressant in this study and how that might be tracking? And then the other question is also on the K2 and three, are there any possibility of some form of an interim analysis in these studies? Thank you.

Hi Yaten, this is Bill, thanks for your question. With respect to how we are ensuring we've got the proper patients being included in K2 and K3 after the pause, the steps that we've taken include having safer clinical team involved in providing the assessment for patients taking one through history, both of depression treatment, our own clinical team is partnering closely with the NGH safer team to ensure that we are providing the degree of oversight that is consistent with our expectations to ensure we have patients with the proper history being enrolled. So we are in fact strengthening that quite a bit and avoiding some of the things that we saw in K1 as part of that. With respect to the interim analysis, we do not have plans for an interim analysis and we are moving ahead with the enrollment and the timelines for K3 being in Q1 and K2

in Q2 of 2026. Our next

question comes from Brian Abraham with RBC Capital Markets.

Hi everyone, thank you for taking my question. This is Nevan for Brian. Just to kind of high level, I guess, what are your kind of your latest views on how to reconcile the core mechanism based on the phase two data that you've shown as well as J&J's, but then also with respect to the COSO 1 study readout and J&J's decision to discontinue a T-comprint or pivot that into different indications. And then I have a follow up after as

well. Sure Nevan, this is Bill, let me start here. We were surprised by J&J's decision to terminate their program given their January of 2025 communication about submitting an NDA later this year. We're looking forward to the presentation of their pool data later this month. That being said, there are several important differences between nevacoprant and a tickerprint as well as the development strategies that are employed with each of the agents. First off, from a pharmacology point of view, nevacoprant is significantly more selective for cap opioid receptors over new opioid receptors than the tickerprint is. Secondly, the study design for each of the programs and molecules were different. We believe the coastal program really reflects the most appropriate study design for this mechanism to be utilized in the monotherapy setting. The steps that we've taken for enhancing K2, K3 really in our view improve the probability of success with the changes that we're making. I would simply say that it's difficult to think about the tickerprint program in read throughs that are limitations due to the pharmacology and study design that limit that read through. We remain confident in nevacoprant still believe postal one results may have been an anomalous finding. We're excited about K2, K3 progressing and the timing for those reading out.

Great, thanks so much. And then I also found the 10Q that was released that triggers the second crunch of funding from PBT for selection of an NLRP3 candidate. So I guess what can you tell us about this early program when we could see more from this and when you might be able to disclose more data about learning this

program? Yeah, Navin, this is Josh here. Thanks for the question, appreciate that. NLRP3 has been a program that we've been very excited about and progressing for a while now. And really, it's focused around targeting the NLRP3 in flammosome, which we believe is a critical part of the innate immune system and can have an impact on a range of CNS as well as other conditions. We tend not to talk a lot about our programs until we move them into the clinic. And as you've noted, we have been making progress with our NLRP3 program. And so looking forward to having more specific updates on that program as we move through the next few quarters and into early

2026. Great, thank you so much.

Our next question comes from Greg Suvanovich with Mizuho Securities.

Hey, good afternoon. Thanks for taking my questions. Appreciate the updates that you've provided. Two questions each on pipeline candidates. Just with respect to 511 and the readout in Alzheimer's disease agitation, maybe could you put in perspective what you expect to see with that data set, especially relative to the data, the phase three data sets that exist for a competitor product, AXS05 from Axome Therapeutics. And then secondly on the M4 PAM, maybe if you could revisit kind of your thoughts on differentiation between your candidate and perhaps the other program and Rackladine in which unfortunately the phase two, three data weren't great, any color as to the confidence that you have that you'll perhaps show a different set of outcomes. Thanks.

Hey Greg, this is Bill. Thanks for your question. Let me start out here with the 511 question. And just as a reminder, this is a study that hasn't been powered to show statistical separation of active from placebo, but is rather a signal seeking study. Two parts, part A of the phase one B, truly the randomized double blind placebo controlled cohort designed to evaluate safety, efficacy, tolerability, PK and healthy elderly volunteers. That portion has been completed. Part B of the phase one B is a multi-center randomized double blind placebo controlled study where we're evaluating NMRA 511, 20 milligrams twice a day in about 88 patients relative to placebo and agitation associated with Alzheimer's. The primary endpoint for the signal seeking study is the change from baseline to week eight on the CMAI or the Cohen-Mansfield agitation inventory. And so we're looking at the total score change there. And we're really looking at these data to help better understand which domains on the CMAI improve and it helped inform our thinking about the design for the next phase of

study that would follow looking at these results. With respect, Greg to the M4. Yeah, Greg,

this is Josh. In terms of the M4 differentiation, one of the areas we've been very focused on engineering is ensuring that our compounds have high blood brain barrier penetration. We think given the class, the cardiovascular related AEs being one of the key limiters for the M4 muscarinics, that really ensuring optimal blood brain barrier penetration is gonna provide the biggest chance to show a great central effect. And so in terms of areas where we think we could differentiate, we do think CNS penetration is one of them. We look forward to providing more specific details on our M4 PAM programs when we bring the next set into the clinic by middle of 2025.

Okay, thank you very much.

Our next question comes from John Boyle with William Blair.

Hi, this is John on for MilesMITER. Thanks so much for taking our question. I was just wondering if you could talk a little bit about maybe potential timing for when you might decide to increase enrollment in coastal two or coastal three, and also just what aspects of the blinded data are you looking at and considering when making that decision? Thanks.

Sure, hi John, this is Bill. I'll start here and basically communicate that with coastal two and three, those studies were designed and scheduled to randomize up to 332 patients into the protocol. We've built in flexibility that allows us to go 25% higher than that 332. With respect to coastal one, you'll recall that we were just north of 380 patients enrolled. So we did end up about 15% over the 332 patients. So we're still in the upper end rolling relative to the 332 base. K2 and K3 are progressing. We haven't made a decision on what that overall number will be, but we'll provide updates

at the appropriate time point.

Our

next question comes

from Ami Fadia with Needham and Company.

Hi, this is Purnah on for Ami. Thank you for taking our question. Just curious, in coastal one, how does the mattress baseline scores compare with the severity that was seen in the phase two study where you saw the differentiation? And also just wanted to understand what is the mix of females that you're seeing now in K2 and K3 and if you're managing the mix of patients. Thank you.

Sure, so looking at K1 relative to phase two, in phase two, we utilized the HAMD 17. And in that study, there were about 100 patients that had moderate to severe MDD. In coastal one, we were utilizing the mattress and we were using a cutoff of 25 or higher on the mattress consistent with a moderate to severe MDD population. So once you think about those populations as being similar with respect to disease severity in that manner. When we think about the mix of subjects in K2 and K3 relative to coastal one, it was a bit anomalous to see the high percentage of males in K1 relative to historically conducted studies. In K2, K3, we are seeing a mix that's more representative of what's historically been seen, roughly two thirds female, one third male. And we're pleased to see that being the demographic sex

distribution for

K2, K3. Got it, thank you.

That concludes today's question and answer session. I'd like to turn the call back to Paul Burns for closing remarks.

All right, thank you, operator, and thank you for all of your questions to the participants in today's call. We very much appreciated the opportunity to give you the quarterly update. And I'd also like to thank my fellow New Moora team members for their commitment to excellence as we advance the programs with the goal of bringing novel new therapeutics to treat patients with brain disease. With that, I bid you adieu and a good afternoon.

This concludes today's conference call. Thank you for participating. You may now disconnect.